Processa Financial Statements From 2010 to 2025

PCSA Stock  USD 0.22  0  0.91%   
Processa Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Processa Pharmaceuticals' valuation are provided below:
Market Capitalization
11 M
Earnings Share
(2.31)
We have found one hundred twenty available trending fundamental ratios for Processa Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Processa Pharmaceuticals recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.

Processa Pharmaceuticals Total Revenue

0.0

Check Processa Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Processa Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 108.1 K, Selling General Administrative of 3 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 95.02, Dividend Yield of 0.0 or PTB Ratio of 1.51. Processa financial statements analysis is a perfect complement when working with Processa Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Processa Stock
Check out the analysis of Processa Pharmaceuticals Correlation against competitors.
For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.

Processa Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.1 M3.2 M7.1 M
Slightly volatile
Property Plant And Equipment Net121.7 K75.7 K140.8 K
Very volatile
Common Stock Shares Outstanding1.7 M3.1 M1.5 M
Slightly volatile
Liabilities And Stockholders Equity3.1 M3.2 M7.1 M
Slightly volatile
Short and Long Term Debt Total69.8 K73.5 K952.5 K
Slightly volatile
Total Current Liabilities1.3 M1.5 M1.2 M
Pretty Stable
Cash1.1 M1.2 M3.6 M
Slightly volatile
Net Receivables61.4 K80.8 K68.5 K
Slightly volatile
Common Stock Total Equity1.5 K1.6 K1.4 K
Slightly volatile
Total Liabilities1.5 M1.5 M1.9 M
Slightly volatile
Total Current Assets1.8 M1.9 M4.1 M
Slightly volatile
Short Term Debt138.7 K146 K581.9 K
Slightly volatile
Current Deferred Revenue584.3 K556.5 K328.5 K
Slightly volatile
Accounts Payable924.9 K880.9 K251.5 K
Slightly volatile
Net Invested Capital1.6 M1.7 M6.6 M
Slightly volatile
Capital Stock3523712.6 K
Slightly volatile

Processa Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General AdministrativeM4.8 M2.8 M
Slightly volatile
Other Operating Expenses6.8 M12.1 M6.2 M
Slightly volatile
Research Development7.6 M7.3 M3.1 M
Slightly volatile
Cost Of Revenue743782311.2 K
Pretty Stable
Total Operating Expenses6.6 M12.1 M6.1 M
Slightly volatile
Selling And Marketing Expenses190200418.1 K
Slightly volatile
Reconciled Depreciation743782251.9 K
Slightly volatile

Processa Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow1.1 M1.2 M3.6 M
Slightly volatile
Stock Based Compensation598 K629.5 K1.2 M
Slightly volatile
Begin Period Cash Flow4.5 M4.7 MM
Slightly volatile
Depreciation743782343.7 K
Pretty Stable
Net Borrowings1.4 M776.2 K1.7 M
Slightly volatile
Issuance Of Capital Stock7.1 M7.8 M4.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio95.0290.562.9798
Slightly volatile
Days Sales Outstanding2.612.7528.5166
Slightly volatile
Average Payables626.1 K596.2 K237.3 K
Slightly volatile
Stock Based Compensation To Revenue1.411.541.4683
Slightly volatile
Capex To Depreciation3.944.148311.9147
Very volatile
EV To Sales378360259
Slightly volatile
Inventory Turnover0.560.590.9588
Slightly volatile
Days Of Inventory On Hand342636555
Slightly volatile
Payables Turnover8.0E-49.0E-41.6944
Pretty Stable
Sales General And Administrative To Revenue72.6869.2168.4708
Slightly volatile
Average Inventory99.2 K98.6 K101.2 K
Slightly volatile
Research And Ddevelopement To Revenue2.351.511.7519
Pretty Stable
Capex To Revenue4.494.283.2733
Slightly volatile
Cash Per Share0.370.389373.034
Slightly volatile
Days Payables Outstanding431.7 K411.2 K87.6 K
Slightly volatile
Income Quality0.520.94890.6467
Very volatile
Intangibles To Total Assets0.660.350.5781
Slightly volatile
Current Ratio1.161.22254.7075
Pretty Stable
Receivables Turnover144138115
Slightly volatile
Capex Per Share0.0010.001116.1371
Slightly volatile
Average Receivables23.9 K12.4 K19.5 K
Slightly volatile
Revenue Per Share0.490.5110.2843
Slightly volatile
Interest Debt Per Share0.02280.02496.2912
Slightly volatile
Debt To Assets0.02160.022832.1323
Very volatile
Operating Cycle670638588
Slightly volatile
Days Of Payables Outstanding431.7 K411.2 K87.6 K
Slightly volatile
Long Term Debt To Capitalization0.00210.00220.0918
Slightly volatile
Quick Ratio1.161.22254.6742
Pretty Stable
Net Income Per E B T1.091.10.9876
Very volatile
Cash Ratio0.740.77734.1893
Pretty Stable
Days Of Inventory Outstanding342636555
Slightly volatile
Days Of Sales Outstanding2.612.7528.5166
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.21.00031.0833
Pretty Stable
Fixed Asset Turnover0.190.246.9205
Pretty Stable
Debt Ratio0.02160.022832.1323
Very volatile
Price Sales Ratio95.0290.562.9798
Slightly volatile
Asset Turnover1.461.391.0335
Slightly volatile

Processa Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market CapM3.1 M34.9 M
Slightly volatile
Enterprise Value1.7 M1.8 M24.2 M
Slightly volatile

Processa Fundamental Market Drivers

Cash And Short Term Investments1.2 M

Processa Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Processa Pharmaceuticals Financial Statements

Processa Pharmaceuticals stakeholders use historical fundamental indicators, such as Processa Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Processa Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Processa Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Processa Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Processa Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue556.5 K584.3 K
Cost Of Revenue 782.00  742.90 
Stock Based Compensation To Revenue 1.54  1.41 
Sales General And Administrative To Revenue 69.21  72.68 
Research And Ddevelopement To Revenue 1.51  2.35 
Capex To Revenue 4.28  4.49 
Revenue Per Share 0.51  0.49 
Ebit Per Revenue(441.95)(419.85)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Processa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Processa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Processa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Processa Pharmaceuticals Stock:
Check out the analysis of Processa Pharmaceuticals Correlation against competitors.
For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.31)
Return On Assets
(1.03)
Return On Equity
(2.12)
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.